Aligos Therapeutics, Inc. logo

Aligos Therapeutics, Inc.

1799448

Aligos Therapeutics is a clinical-stage biotechnology company headquartered in South San Francisco, California. They are focused on developing best-in-class therapies for liver and viral diseases, specifically targeting areas with high unmet medical needs. Their pipeline includes treatments for chronic HBV infection and MASH. Aligos aims to significantly improve patient outcomes through science-driven approaches and a patient-centric focus.

86
Highly Trusted
Trust Score

Official Registry

Legal Name
Aligos Therapeutics, Inc.
Organization Number
1799448
VAT Number
000000000
Company Status
Active
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA 94080
Industry Codes
Biological Products, (No Diagnostic Substances), 2836

AI Quality Analysis

Industry
Biotechnology
SSL/HTTPS
Secure
Professional Email
Yes
Contact Email
info@aligos.com

🌟 Similar Trusted Businesses

Metagenomi, Inc.

Metagenomi, Inc. logo
74/100 · Trusted

Metagenomi is an in vivo genome editing company creating curative genetic medicines using proprietary technologies. They leverage metagenomics to discover editing tools potentially capable of correcting any type of genetic mutation. The company focuses on diseases with well-understood biology and clear regulatory pathways, and intends to expand their pipeline through genetic editing capabilities.

5959 HORTON STREET, USA
View Profile

ARCTICZYMES TECHNOLOGIES ASA

ARCTICZYMES TECHNOLOGIES ASA logo
80/100 · Highly Trusted

ArcticZymes Technologies is a biotechnology company specializing in the development and production of enzymes. They offer nucleases for biomanufacturing and molecular diagnostics, including Salt Active Nucleases (SAN). The company is known for its polymerases and enzymes used in research and industrial applications.

Sykehusvegen 23, Norway
View Profile

ACD PHARMACEUTICALS AS

ACD PHARMACEUTICALS AS logo
80/100 · Highly Trusted

ACD Pharma is a Norwegian R&D company developing biocontrol products based on bacteriophages, focusing on combating harmful bacteria in animals and humans. They launched Custus®YRS, the world's first bacteriophage product for aquaculture. They collaborate with pharmaceutical and scientific teams to fight antibiotic resistance, extending their advancements across sectors.

Lofoten Bio Centre, Norway10 employees
View Profile